188 related articles for article (PubMed ID: 25920994)
1. Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Bianco V; Ponchietti R; Barbanti G; Francini E
Clin Genitourin Cancer; 2015 Oct; 13(5):441-6. PubMed ID: 25920994
[TBL] [Abstract][Full Text] [Related]
2. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
[TBL] [Abstract][Full Text] [Related]
3. Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer.
Roviello G; Zanotti L; Gobbi A; Dester M; Generali D; Pacifico C; Cappelletti MR; Bonetta A
Clin Genitourin Cancer; 2017 Jun; 15(3):371-375. PubMed ID: 27692697
[TBL] [Abstract][Full Text] [Related]
4. [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients].
Fukui T; Nakamura K; Sakatani T; Atsuta T; Kato T; Fukumoto T; Ito M; Inoue K; Terai A
Hinyokika Kiyo; 2017 Feb; 63(2):57-62. PubMed ID: 28264534
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
Wong YN; Manola J; Hudes GR; Roth BJ; Moul JW; Barsevick AM; Scher RM; Volk MJ; Vaughn DJ; Williams SD; Fisch MJ; Cella D; Carducci MA; Wilding G
Clin Genitourin Cancer; 2018 Apr; 16(2):e315-e322. PubMed ID: 29173976
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer.
Laber DA; Chen MB; Jaglal M; Patel A; Visweshwar N
Clin Genitourin Cancer; 2018 Dec; 16(6):473-481. PubMed ID: 30072309
[TBL] [Abstract][Full Text] [Related]
9. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.
Nakano K; Ohta S; Komatsu K; Kubo T; Nukui A; Suzuki K; Kurokawa S; Kobayashi M; Morita T
BMC Urol; 2012 Feb; 12():3. PubMed ID: 22353627
[TBL] [Abstract][Full Text] [Related]
11. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer.
Francini E; Fiaschi AI; Petrioli R; Francini F; Bianco V; Perrella A; Paganini G; Laera L; Roviello G
Anticancer Drugs; 2014 Apr; 25(4):472-7. PubMed ID: 24394473
[TBL] [Abstract][Full Text] [Related]
13. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
Hatano K; Nishimura K; Nakai Y; Yoshida T; Sato M; Kawashima A; Mukai M; Nagahara A; Uemura M; Oka D; Nakayama M; Takayama H; Shimizu K; Meguro N; Tanigawa T; Yamaguchi S; Tsujimura A; Nonomura N
Int J Clin Oncol; 2013 Aug; 18(4):704-10. PubMed ID: 22688162
[TBL] [Abstract][Full Text] [Related]
14. Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.
Petrioli R; Francini E; Fiaschi AI; Laera L; Miano ST; De Rubertis G; Roviello G
Anticancer Res; 2015 May; 35(5):3097-102. PubMed ID: 25964601
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
Chittoor S; Berry W; Loesch D; Logie K; Fleagle J; Mull S; Boehm KA; Zhan F; Asmar L
Clin Genitourin Cancer; 2006 Dec; 5(3):212-8. PubMed ID: 17239275
[TBL] [Abstract][Full Text] [Related]
16. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
Qin Z; Li X; Zhang J; Tang J; Han P; Xu Z; Yu Y; Yang C; Wang C; Xu T; Xu Z; Zou Q
Medicine (Baltimore); 2016 Sep; 95(39):e4801. PubMed ID: 27684806
[TBL] [Abstract][Full Text] [Related]
18. Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience.
Sciarra A; Gentile V; Cattarino S; Gentilucci A; Alfarone A; D'Eramo G; Salciccia S
Int J Urol; 2015 Jan; 22(1):98-103. PubMed ID: 25186970
[TBL] [Abstract][Full Text] [Related]
19. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
Dawson NA; Halabi S; Ou SS; Biggs DD; Kessinger A; Vogelzang N; Clamon GH; Nanus DM; Kelly WK; Small EJ;
Clin Genitourin Cancer; 2008 Sep; 6(2):110-6. PubMed ID: 18824434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
